Continuous infusion of hydrocortisone reduces hyperglyaemia in patients with septic shock

Key points
- Changing how critically ill patients are treated with hydrocortisone could reduce hyperglycemia.
- Low dose hydrocortisone treatment is widely used as a treatment for patients suffering from septic shock.
- Pekka Loisa of the Päijät-Häme Hospital in Finland, and colleagues from hospitals throughout Finland carried out the trial involving 48 patients in four intensive care units (ICUs) between July 2005 and April 2006.
- Loisa et al. found that the mean blood glucose levels were similar in both groups, but the number of hyperglycaemic episodes was higher in the group receiving bolus therapy.
Changing how critically ill patients are treated with hydrocortisone could reduce hyperglycemia. The results of a randomized controlled clinical trial, published today in the journal Critical Care, lead researchers to recommend using continuous infusion of low-dose hydrocortisone in patients with sepsis, rather than bolus injections. The study shows that continuous infusion of low-dose hydrocortisone minimizes hyperglycaemic episodes, serious adverse events that can lead to insulin dependency. The researchers also found that continuous infusion reduced nurses’ workload.
Low dose hydrocortisone treatment is widely used as a treatment for patients suffering from septic shock. However, hydrocortisone stimulates glucose production in the liver and other tissues and may induce high blood glucose levels, or hyperglycaemia. Preventing hyperglycaemia has previously been shown to improve the survival of critically ill patients.
Pekka Loisa of the Päijät-Häme Hospital in Finland, and colleagues from hospitals throughout Finland carried out the trial involving 48 patients in four intensive care units (ICUs) between July 2005 and April 2006. One group of 24 patients received the hydrocortisone treatment by continuous infusion of 200mg/day. The bolus therapy group of 24 patients received the same overall dose, but the hydrocortisone was administered intravenously in 50mg doses every six hours. Loisa et al. compared blood glucose levels, insulin requirements and the nursing workload for the two groups. Hydrocortisone treatment lasted five days in both groups.
Loisa et al. found that the mean blood glucose levels were similar in both groups, but the number of hyperglycaemic episodes was higher in the group receiving bolus therapy. For patients undergoing bolus therapy, the insulin infusion rate had to be changed more often to maintain normal blood glucose levels, adding to nurses’ workload. The researchers stress that normal blood glucose levels can be achieved successfully using both methods. However, strict normoglycemia is more easily achieved with continuous hydrocortisone infusion.
###
Article:
Effect of hydrocortisone treatment modality on glycemic control in patients with septic shock. A prospective randomized trial Pekka Loisa, Ilkka Parviainen, Jyrki Tenhunen, Seppo Hovilehto and Esko Ruokonen Critical Care 2007 (in press)
BioMed Central
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Diabetes & Hormones →
NewsPlant hormone may play a vital role in blood sugar control and diabetes management
A treatment for managing blood sugar levels might be as close as the local health food store, suggests a new research report published in the December 2015 issue of The FASEB Journal. Specifically scientists from Italy…
2 December 2015
NewsGenetic variant shown to influence women's body shape and diabetes risk
A genetic variant near the KLF14 gene regulates hundreds of genes that govern how and where women's bodies store fat, which affects their risk of developing Type 2 diabetes, according to research presented at the…
13 October 2015
NewsSatiety hormone leptin plays a direct role in cardiovascular disease in obesity
While high levels of the satiety hormone leptin don't help obese individuals lose weight, they do appear to directly contribute to their cardiovascular disease, researchers report. "With obesity, leptin cannot tell our…







